SAN FRANCISCO, March 10, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today ...
SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UBX) (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases ...
Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary endpoint and the only time stamp out of 10 in which the candidate was ...
SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today ...
In a report released today, Andreas Argyrides from Wedbush reiterated a Buy rating on Unity Biotechnology (UBX – Research Report), with a price target of $35.00. The company’s shares closed yesterday ...
"I look forward to collaborating with the UNITY team to advance the lead senolytic program and shape an exciting pipeline of future products." Keith R. Leonard Jr., chairman of the board of UNITY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results